BR112015022945A8 - Partículas de fenilefrina revestidas de liberação estendida - Google Patents

Partículas de fenilefrina revestidas de liberação estendida

Info

Publication number
BR112015022945A8
BR112015022945A8 BR112015022945A BR112015022945A BR112015022945A8 BR 112015022945 A8 BR112015022945 A8 BR 112015022945A8 BR 112015022945 A BR112015022945 A BR 112015022945A BR 112015022945 A BR112015022945 A BR 112015022945A BR 112015022945 A8 BR112015022945 A8 BR 112015022945A8
Authority
BR
Brazil
Prior art keywords
extended release
release coated
phenylephrine particles
coated phenylephrine
particles
Prior art date
Application number
BR112015022945A
Other languages
English (en)
Other versions
BR112015022945B1 (pt
BR112015022945A2 (pt
Inventor
Lee Der-Yang
Chen Vincent
Shen Robert
Original Assignee
Johnson & Johnson Consumer Inc
Currahee Holding Company Inc
Chenango Zero Llc
Chenango Two Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc, Currahee Holding Company Inc, Chenango Zero Llc, Chenango Two Llc filed Critical Johnson & Johnson Consumer Inc
Publication of BR112015022945A2 publication Critical patent/BR112015022945A2/pt
Publication of BR112015022945A8 publication Critical patent/BR112015022945A8/pt
Publication of BR112015022945B1 publication Critical patent/BR112015022945B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

PARTÍCULAS DE FENILEFRINA REVESTIDAS E SEU USO EM FORMULAÇÕES FARMACÊUTICAS. A presente invenção descreve partículas de fenilefrina adequadas para formas de dosagem sólidas, líquidas ou semissólidas.
BR112015022945-0A 2013-03-15 2014-02-28 Partículas de fenilefrina revestidas de liberação estendida BR112015022945B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/832,797 US20140271893A1 (en) 2013-03-15 2013-03-15 Coated phenylephrine particles and use thereof in pharmaceutical formulations
US13/832,797 2013-03-15
PCT/US2014/019311 WO2014149529A1 (en) 2013-03-15 2014-02-28 Coated phenylephrine particles and use thereof in pharmaceutical formulations

Publications (3)

Publication Number Publication Date
BR112015022945A2 BR112015022945A2 (pt) 2017-07-18
BR112015022945A8 true BR112015022945A8 (pt) 2022-08-09
BR112015022945B1 BR112015022945B1 (pt) 2022-11-01

Family

ID=50288314

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022945-0A BR112015022945B1 (pt) 2013-03-15 2014-02-28 Partículas de fenilefrina revestidas de liberação estendida

Country Status (18)

Country Link
US (1) US20140271893A1 (pt)
EP (1) EP2968188B1 (pt)
JP (1) JP6373957B2 (pt)
CN (1) CN105246466B (pt)
AR (1) AR095526A1 (pt)
AU (1) AU2014238062B2 (pt)
BR (1) BR112015022945B1 (pt)
CA (1) CA2906363C (pt)
HK (1) HK1219886A1 (pt)
IL (1) IL241051B (pt)
MX (1) MX2015012635A (pt)
NZ (1) NZ712318A (pt)
PH (1) PH12015502015B1 (pt)
RU (1) RU2681312C2 (pt)
SA (1) SA515361065B1 (pt)
UA (1) UA120251C2 (pt)
WO (1) WO2014149529A1 (pt)
ZA (1) ZA201507676B (pt)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
WO1998027961A2 (en) 1996-12-20 1998-07-02 Warner Lambert Company Antitussive drugs delivered by partially coated ion exchange resins
HUP0302631A2 (hu) * 2000-03-30 2003-11-28 Bristol-Myers Squibb Co. Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US7639628B2 (en) 2005-07-14 2009-12-29 University Of Notre Dame Du Lac Response time detection in a network having shared interfaces
RU2435569C2 (ru) 2006-03-16 2011-12-10 Трис Фарма, Инк. Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола
AR061166A1 (es) 2006-06-01 2008-08-06 Schering Corp Composiciones farmaceuticas para la liberacion sostenida de fenilferina
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US20070292510A1 (en) * 2006-06-19 2007-12-20 Hugh Huang Enteric coated particles containing an active ingredient
US8394415B2 (en) 2006-11-21 2013-03-12 Mcneil-Ppc, Inc Modified release analgesic suspensions
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
BRPI0915411A2 (pt) * 2008-06-26 2015-11-03 Mcneil Ppc Inc partículas revestidas contendo agentes farmaceuticamente ativos
WO2012020097A2 (en) * 2010-08-13 2012-02-16 Euro-Celtique S.A. Use of binders for manufacturing storage stable formulations
RU2477741C1 (ru) * 2012-04-27 2013-03-20 Юрий Васильевич Захаров Состав мульчирующего покрытия (варианты)

Also Published As

Publication number Publication date
EP2968188B1 (en) 2017-04-19
JP6373957B2 (ja) 2018-08-15
CN105246466B (zh) 2018-03-30
RU2015144045A (ru) 2017-04-20
ZA201507676B (en) 2017-11-29
UA120251C2 (uk) 2019-11-11
CA2906363A1 (en) 2014-09-25
CA2906363C (en) 2021-03-16
MX2015012635A (es) 2016-08-03
AU2014238062B2 (en) 2018-11-29
PH12015502015A1 (en) 2016-01-11
RU2681312C2 (ru) 2019-03-06
IL241051A0 (en) 2015-11-30
CN105246466A (zh) 2016-01-13
SA515361065B1 (ar) 2017-02-02
WO2014149529A1 (en) 2014-09-25
EP2968188A1 (en) 2016-01-20
US20140271893A1 (en) 2014-09-18
AU2014238062A1 (en) 2015-09-17
BR112015022945B1 (pt) 2022-11-01
PH12015502015B1 (en) 2016-01-11
JP2016516029A (ja) 2016-06-02
AR095526A1 (es) 2015-10-21
HK1219886A1 (zh) 2017-04-21
BR112015022945A2 (pt) 2017-07-18
NZ712318A (en) 2020-05-29
IL241051B (en) 2018-06-28

Similar Documents

Publication Publication Date Title
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112016003480A2 (pt) ensaios para detecção de molécula única e seu uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
BR112015007642A2 (pt) kits e formas de dosagem oral contendo progesterona.
BR112015002767A2 (pt) composições, métodos, e sistemas para a síntese e uso de agentes de imagiologia
BR112017020358A2 (pt) composição farmacêutica de tetraciclina para uso dermatológico
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
BR112015019897A2 (pt) granulador de rolos de esmagamento, sistema e uso
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BR112017008854A2 (pt) partículas de cadotrila
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
CL2018000403A1 (es) Compuestos para uso en aplicaciones antibacterianas.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: CHENANGO ZERO LLC (US)

B25A Requested transfer of rights approved

Owner name: CHENANGO TWO LLC (US)

B25A Requested transfer of rights approved

Owner name: CURRAHEE HOLDING COMPANY INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2014, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)

B25D Requested change of name of applicant approved

Owner name: JOHNSON AND JOHNSON CONSUMER INC. (US)